Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
Trial details
- Registry ID
- NCT02175004
- Phase
- Phase 3
The FDA approved Inotersen (IONIS-TTR Rx) on 5 Oct 2018.
Drug identity checked against registry records
Also recorded as IONIS-TTR Rx; ISIS 420915; TEGSEDI
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)NCT02175004 | IONS | Phase 3 | Completed | 2020-09-11Actual |
| NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid PolyneuropathyNCT04136184 | IONS | Phase 3 | Completed | 2023-04-11Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2018-10-05Day | Inotersen | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA211172", "applicant_as_listed_by_fda": "AKCEA THERAPS", "brand_names": ["TEGSEDI"], "active_ingredients": ["INOTERSEN SODIUM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20181005", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |